Bupivacaine (Marcaine, Sensorcaine, Exparel (liposomal formulation))
Other Medications · Approved since 1963
Description
Bupivacaine is a long-acting local anesthetic from the amide class that is used in colorectal cancer surgery to provide extended post-operative pain control. In CRC treatment, it serves as a supportive care medication to manage surgical pain following colectomy and other colorectal procedures. The drug is particularly valuable in enhanced recovery protocols where minimizing opioid use and facilitating early mobilization are key goals.
Mechanism of Action
Bupivacaine blocks voltage-gated sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses that transmit pain signals. This sodium channel blockade occurs at the site of injection, providing localized anesthesia that can last 8-12 hours depending on the formulation and injection site.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Marcaine, Sensorcaine, Exparel (liposomal formulation) |
| Category | Other Medications |
 Status | FDA Approved |
| Administration | Topical |
| Year Approved | 1963 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.